{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:23:17Z","timestamp":1793726597969,"version":"4.6.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-025-03056-1","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T12:03:43Z","timestamp":1769688223000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risk score for lower-limb amputation and its ability to predict major kidney and cardiovascular events in people with type 1 diabetes"],"prefix":"10.1186","volume":"25","author":[{"given":"Marion","family":"Camoin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Potier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Larroumet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Rigalleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Hadjadj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Scheen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"Velho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Marre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Jean","family":"Saulnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamel","family":"Mohammedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"3056_CR1","doi-asserted-by":"crossref","unstructured":"\u00d3lafsd\u00f3ttir AF, Svensson AM, Pivodic A, Gudbj\u00f6rnsdottir S, Nystr\u00f6m T, Wedel H, et al. Excess risk of lower extremity amputations in people with type 1 diabetes compared with the general population: amputations and type 1 diabetes. BMJ Open Diab Res Care [Internet]. 2019 Apr 14 [cited 2025 Mar 2];7(1). Available from: https:\/\/drc.bmj.com\/content\/7\/1\/e000602","DOI":"10.1136\/bmjdrc-2018-000602"},{"issue":"9498","key":"3056_CR2","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/S0140-6736(05)67698-2","volume":"366","author":"AJM Boulton","year":"2005","unstructured":"Boulton AJM, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet. 2005;366(9498):1719\u201324.","journal-title":"Lancet"},{"issue":"8","key":"3056_CR3","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/dme.13973","volume":"36","author":"M Kerr","year":"2019","unstructured":"Kerr M, Barron E, Chadwick P, Evans T, Kong WM, Rayman G, et al. The cost of diabetic foot ulcers and amputations to the National Health Service in England. Diabet Med. 2019;36(8):995\u20131002.","journal-title":"Diabet Med"},{"issue":"5","key":"3056_CR4","doi-asserted-by":"publisher","first-page":"964","DOI":"10.2337\/dc19-1614","volume":"43","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Lazzarini PA, McPhail SM, van Netten JJ, Armstrong DG, Pacella RE. Global disability burdens of diabetes-related lower-extremity complications in 1990 and 2016. Diabetes Care. 2020;43(5):964\u201374.","journal-title":"Diabetes Care"},{"issue":"1","key":"3056_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12933-022-01487-8","volume":"21","author":"M Camoin","year":"2022","unstructured":"Camoin M, Velho G, Saulnier PJ, Potier L, Abouleka Y, Carpentier C, et al. Differential prognostic burden of cardiovascular disease and lower-limb amputation on the risk of all-cause death in people with long-standing type 1 diabetes. Cardiovasc Diabetol. 2022;21(1):71.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"3056_CR6","doi-asserted-by":"publisher","first-page":"878","DOI":"10.2337\/dc09-2007","volume":"33","author":"A Ndip","year":"2010","unstructured":"Ndip A, Lavery LA, LaFontaine J, Rutter MK, Vardhan A, Vileikyte L, et al. High levels of foot ulceration and amputation risk in a multiracial cohort of diabetic patients on dialysis therapy. Diabetes Care. 2010;33(4):878\u201380.","journal-title":"Diabetes Care"},{"issue":"24","key":"3056_CR7","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1056\/NEJMra1615439","volume":"376","author":"DG Armstrong","year":"2017","unstructured":"Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med. 2017;376(24):2367\u201375.","journal-title":"N Engl J Med"},{"issue":"1","key":"3056_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12933-015-0322-0","volume":"15","author":"K Mohammedi","year":"2016","unstructured":"Mohammedi K, Potier L, Belhatem N, Matallah N, Hadjadj S, Roussel R, et al. Lower-extremity amputation as a marker for renal and cardiovascular events and mortality in patients with long standing type 1 diabetes. Cardiovasc Diabetol. 2016;15(1):5.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"3056_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12933-020-01198-y","volume":"20","author":"K Mohammedi","year":"2021","unstructured":"Mohammedi K, Harrap S, Mancia G, Marre M, Poulter N, Chalmers J, et al. History of lower-limb complications and risk of cancer death in people with type 2 diabetes. Cardiovasc Diabetol. 2021;20(1):3.","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"3056_CR10","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1161\/CIRCULATIONAHA.115.018844","volume":"133","author":"D Vistisen","year":"2016","unstructured":"Vistisen D, Andersen GS, Hansen CS, Hulman A, Henriksen JE, Bech-Nielsen H, et al. Prediction of first cardiovascular disease event in type 1 diabetes mellitus: the steno type 1 risk engine. Circulation. 2016;133(11):1058\u201366.","journal-title":"Circulation"},{"issue":"4","key":"3056_CR11","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2337\/dc20-2586","volume":"44","author":"D Vistisen","year":"2021","unstructured":"Vistisen D, Andersen GS, Hulman A, McGurnaghan SJ, Colhoun HM, Henriksen JE, et al. A validated prediction model for end-stage kidney disease in type 1 diabetes. Diabetes Care. 2021;44(4):901\u20137.","journal-title":"Diabetes Care"},{"issue":"12","key":"3056_CR12","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1007\/s00125-021-05550-z","volume":"64","author":"S Hallstr\u00f6m","year":"2021","unstructured":"Hallstr\u00f6m S, Svensson AM, Pivodic A, \u00d3lafsd\u00f3ttir AF, L\u00f6ndahl M, Wedel H, et al. Risk factors and incidence over time for lower extremity amputations in people with type 1 diabetes: an observational cohort study of 46,088 patients from the Swedish National Diabetes Registry. Diabetologia. 2021;64(12):2751\u201361.","journal-title":"Diabetologia"},{"issue":"2","key":"3056_CR13","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2337\/dc22-1744","volume":"46","author":"I Bebu","year":"2022","unstructured":"Bebu I, Braffett BH, de Boer IH, Aiello LP, Bantle JP, Lorenzi GM, et al. Relationships between the cumulative incidences of long-term complications in type 1 diabetes: the DCCT\/EDIC study. Diabetes Care. 2022;46(2):361\u20138.","journal-title":"Diabetes Care"},{"issue":"7","key":"3056_CR14","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1172\/JCI119321","volume":"99","author":"M Marre","year":"1997","unstructured":"Marre M, Jeunemaitre X, Gallois Y, Rodier M, Chatellier G, Sert C, et al. Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. J Clin Invest. 1997;99(7):1585\u201395.","journal-title":"J Clin Invest"},{"issue":"11","key":"3056_CR15","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.2337\/diacare.27.11.2661","volume":"27","author":"S Hadjadj","year":"2004","unstructured":"Hadjadj S, P\u00e9an F, Gallois Y, Passa P, Aubert R, Weekers L, et al. Different patterns of insulin resistance in relatives of type 1 diabetic patients with retinopathy or nephropathy: the genesis France\u2013Belgium study. Diabetes Care. 2004;27(11):2661\u20138.","journal-title":"Diabetes Care"},{"issue":"3","key":"3056_CR16","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1681\/ASN.V123541","volume":"12","author":"S Hadjadj","year":"2001","unstructured":"Hadjadj S, Belloum R, Bouhanick B, Gallois Y, Guilloteau G, Chatellier G, et al. Prognostic value of angiotensin-I converting enzyme I\/D polymorphism for nephropathy in type 1 diabetes mellitus: a prospective study. J Am Soc Nephrol. 2001;12(3):541\u20139.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"3056_CR17","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"issue":"446","key":"3056_CR18","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496\u2013509.","journal-title":"J Am Stat Assoc"},{"issue":"13","key":"3056_CR19","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1002\/sim.1802","volume":"23","author":"MJ Pencina","year":"2004","unstructured":"Pencina MJ, D\u2019Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004;23(13):2109\u201323.","journal-title":"Stat Med"},{"issue":"2","key":"3056_CR20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1023\/A:1009612305785","volume":"4","author":"S May","year":"1998","unstructured":"May S, Hosmer DW. A simplified method of calculating an overall goodness-of-fit test for the cox proportional hazards model. Lifetime Data Anal. 1998;4(2):109\u201320.","journal-title":"Lifetime Data Anal"},{"issue":"13","key":"3056_CR21","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New Engl J Med. 2004;351(13):1296\u2013305.","journal-title":"New Engl J Med"},{"issue":"12","key":"3056_CR22","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/ki.2010.536","volume":"79","author":"M Van Der Velde","year":"2011","unstructured":"Van Der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey AS, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79(12):1341\u201352.","journal-title":"Kidney Int"},{"issue":"15","key":"3056_CR23","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1001\/jama.2011.451","volume":"305","author":"N Tangri","year":"2011","unstructured":"Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011;305(15):1553\u20139.","journal-title":"JAMA"},{"issue":"8","key":"3056_CR24","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.2337\/dc06-0290","volume":"29","author":"JC Zgibor","year":"2006","unstructured":"Zgibor JC, Piatt GA, Ruppert K, Orchard TJ, Roberts MS. Deficiencies of cardiovascular risk prediction models for type 1 diabetes. Diabetes Care. 2006;29(8):1860\u20135.","journal-title":"Diabetes Care"},{"issue":"8","key":"3056_CR25","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.2337\/dc11-0331","volume":"34","author":"BA Lipsky","year":"2011","unstructured":"Lipsky BA, Weigelt JA, Sun X, Johannes RS, Derby KG, Tabak YP. Developing and validating a risk score for lower-extremity amputation in patients hospitalized for a diabetic foot infection. Diabetes Care. 2011;34(8):1695\u2013700.","journal-title":"Diabetes Care"},{"issue":"11","key":"3056_CR26","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1007\/s00125-014-3358-x","volume":"57","author":"SS Soedamah-Muthu","year":"2014","unstructured":"Soedamah-Muthu SS, Vergouwe Y, Costacou T, Miller RG, Zgibor J, Chaturvedi N, et al. Predicting major outcomes in type 1 diabetes: a model development and validation study. Diabetologia. 2014;57(11):2304\u201314.","journal-title":"Diabetologia"},{"issue":"3","key":"3056_CR27","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1007\/s00125-020-05326-x","volume":"64","author":"C Bertrand","year":"2021","unstructured":"Bertrand C, Saulnier PJ, Potier L, Croyal M, Blanchard V, Gand E, et al. Plasma concentrations of lipoproteins and risk of lower-limb peripheral artery disease in people with type 2 diabetes: the SURDIAGENE study. Diabetologia. 2021;64(3):668\u201380.","journal-title":"Diabetologia"},{"issue":"4","key":"3056_CR28","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s00125-017-4510-1","volume":"61","author":"M Sanchez","year":"2018","unstructured":"Sanchez M, Roussel R, Hadjadj S, Moutairou A, Marre M, Velho G, et al. Plasma concentrations of 8-hydroxy-2\u2019-deoxyguanosine and risk of kidney disease and death in individuals with type 1 diabetes. Diabetologia. 2018;61(4):977\u201384.","journal-title":"Diabetologia"},{"issue":"14","key":"3056_CR29","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1186\/s12933-014-0163-2","volume":"15","author":"K Mohammedi","year":"2015","unstructured":"Mohammedi K, Bellili-Mu\u00f1oz N, Marklund SL, Driss F, Le Nagard H, Patente TA, et al. Plasma extracellular superoxide dismutase concentration, allelic variations in the SOD3 gene and risk of myocardial infarction and all-cause mortality in people with type 1 and type 2 diabetes. Cardiovasc Diabetol. 2015;15(14):845.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"3056_CR30","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00125-009-1263-5","volume":"52","author":"JWM Nin","year":"2009","unstructured":"Nin JWM, Ferreira I, Schalkwijk CG, Prins MH, Chaturvedi N, Fuller JH, et al. Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB prospective complications study. Diabetologia. 2009;52(4):705\u201314.","journal-title":"Diabetologia"},{"issue":"9","key":"3056_CR31","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1161\/CIRCRESAHA.110.223545","volume":"107","author":"F Giacco","year":"2010","unstructured":"Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058\u201370.","journal-title":"Circ Res"},{"issue":"10","key":"3056_CR32","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.2337\/dc18-0695","volume":"41","author":"M Nativel","year":"2018","unstructured":"Nativel M, Schneider F, Saulnier PJ, Gand E, Ragot S, Meilhac O, et al. Prognostic values of inflammatory and redox status biomarkers on the risk of major lower-extremity artery disease in individuals with type 2 diabetes. Diabetes Care. 2018;41(10):2162\u20139.","journal-title":"Diabetes Care"},{"issue":"12","key":"3056_CR33","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.2337\/dc16-1594","volume":"39","author":"K Mohammedi","year":"2016","unstructured":"Mohammedi K, Woodward M, Zoungas S, Li Q, Harrap S, Patel A, et al. Absence of peripheral pulses and risk of major vascular outcomes in patients with type 2 diabetes. Diabetes Care. 2016;39(12):2270\u20137.","journal-title":"Diabetes Care"},{"issue":"20","key":"3056_CR34","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, Neeland IJ, Tuttle KR, Chow SL, Mathew RO, Khan SS, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American heart association. Circulation. 2023;148(20):1636\u201364.","journal-title":"Circulation"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-03056-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-03056-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-03056-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:07:00Z","timestamp":1773659220000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12933-025-03056-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3056"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-03056-1","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GENEDIAB, GENESIS and SURGENE cohort complied with the Declaration of Helsinki. The study protocol for each cohort was approved by the Ethics Committee of the University Hospital of Angers in France. All participants provided written informed consent prior to the start of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M.C. reports personal fees from Boehringer-Ingelheim, Eli Lilly, Sanofi, and Pierre Fabre. LP reports grants, personal fees and non-financial support from Bayer, Novo Nordisk, Sanofi, Eli Lilly, Boehringer Ingelheim and AstraZeneca. S.H. reports personal fees and non-financial support from AstraZeneca, Sanofi, MSD, and Servier, grants and personal fees from Bayer, personal fees from Boehringer Ingelheim, Eli Lilly, Valbiotis, and Novartis, grants from Dinno Sant\u00e9 and Pierre Fabre Sant\u00e9, non-financial support from LVL. A.S. reports personal fees and non-financial supports from AstraZeneca, Boehringer Ingelheim, Eli Lilly, MSD, Novo Nordisk, and Sanofi. MM reports personal fees for lectures from Novo-Nordisk, Sevier, and Ajanta. PJS reports personal fees and non-financial support from Novo Nordisk, Abbott, Sanofi, and AstraZeneca. K.M. reports consulting fees from Novo Nordisk; honoraria for lectures, presentations, or speaker bureaus from Novo Nordisk, AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Sanofi, Lifescan, Abbott, and Bayer; and participation to Advisory Board from Novo Nordisk, Sanofi, and Amarin. There are no further conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"85"}}